Dicerna Pharmaceuticals, Inc. – NASDAQ:DRNA

Add to watchlist

$38.22

Market closed

Open in 2 days

+70.93%

quarter

+45.10%

year

Market Cap	N/A
Enterprise value	2.87B

P/E	-23.87
EV/Sales	14.88
EV/EBITDA	-24.21
Price/Sales	15.40
Price/Book	27.59
PEG ratio	-1.75
EPS	-1.63

Revenue	192.85M
EBITDA	-118.52M
Income	-124.43M
Revenue Q/Q	28.80%
Revenue Y/Y	47.85%

Profit margin	-64.53%
Oper. margin	-62.88%
Gross margin	21.24%
EBIT margin	-62.88%
EBITDA margin	-61.46%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA): Profit margin
Dec 2020	40.95M	-36.58M	-89.33%
Mar 2021	47.60M	-29.96M	-62.95%
Jun 2021	41.33M	-40.81M	-98.74%
Sep 2021	62.95M	-17.07M	-27.12%

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA): Earnings per share (EPS)
2021-02-25	-0.03	-0.49
2021-05-06	-0.37	-0.39
2021-08-09	0.51	-0.53
2021-11-09	-0.41	-0.22

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA): Debt to assets
Dec 2020	707846000	570.09M	80.54%
Mar 2021	683410000	557.00M	81.5%
Jun 2021	838492000	727.41M	86.75%
Sep 2021	772059000	664.39M	86.06%

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA): Cash Flow
Dec 2020	-47.30M	-41.97M	11.02M
Mar 2021	-26.7M	52.88M	6.15M
Jun 2021	158.83M	-108.60M	11.86M
Sep 2021	-63.78M	5.88M	2.44M

Dicerna Pharmaceuticals alternative data

Dicerna Pharmaceuticals
Employees

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA): Employee count
Aug 2023	302
Sep 2023	302
Oct 2023	302
Nov 2023	302
Dec 2023	302
Jan 2024	302
Feb 2024	302
Mar 2024	302
Apr 2024	302
May 2024	302
Jun 2024	302
Jul 2024	302

Dicerna Pharmaceuticals
Insider Trading

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA): Insider trades (number of shares)
Period	Buy	Sel
Dec 2020	0	1000000
Jan 2021	0	43372
Feb 2021	0	19899
Mar 2021	0	21055
Apr 2021	0	45959
May 2021	0	25486
Jun 2021	0	126837
Jul 2021	0	46624
Aug 2021	8000	8312
Sep 2021	0	36221
Nov 2021	0	24936

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	15 Dec 2021	ZENG LING officer: Chief Legal Officer & Sec'y officer: Chief Legal Officer & ..	Restricted Stock Units	2,562	N/A	N/A
Option	15 Dec 2021	ZENG LING officer: Chief Legal Officer & Sec'y officer: Chief Legal Officer & ..	Common Stock	2,562	N/A	N/A
Option	15 Dec 2021	BROWN BOB D officer: Chief Scientific Ofr., EVP R&D officer: Chief Scientific Ofr.,..	Restricted Stock Units	3,775	N/A	N/A
Option	15 Dec 2021	BROWN BOB D officer: Chief Scientific Ofr., EVP R&D officer: Chief Scientific Ofr.,..	Common Stock	3,775	N/A	N/A
Option	15 Dec 2021	FAMBROUGH DOUGLAS director, officer..	Restricted Stock Units	13,750	N/A	N/A
Option	15 Dec 2021	FAMBROUGH DOUGLAS director, officer..	Common Stock	13,750	N/A	N/A
Option	15 Dec 2021	WEISSMAN JAMES B officer: Chief Op..	Restricted Stock Units	3,775	N/A	N/A
Option	15 Dec 2021	WEISSMAN JAMES B officer: Chief Op..	Common Stock	3,775	N/A	N/A
Option	15 Dec 2021	ARADHYE SHREERAM officer: EVP & Ch..	Restricted Stock Units	2,837	N/A	N/A
Option	15 Dec 2021	ARADHYE SHREERAM officer: EVP & Ch..	Common Stock	2,837	N/A	N/A

DRNA insider trading transactions

Dicerna Pharmaceuticals
Patents

Status	Patent	Filling date	Issue date
Grant	Grant Utility: Extended dicer substrate agents and methods for the specific inhibition of gene expression Filling date: 20 Aug 2021 Issue date: 16 Aug 2022	20 Aug 2021	16 Aug 2022
Grant	Grant Utility: 4'-phosphate analogs and oligonucleotides comprising the same Filling date: 1 Sep 2017 Issue date: 16 Aug 2022	1 Sep 2017	16 Aug 2022
Grant	Grant Utility: Extended dicer substrate agents and methods for the specific inhibition of gene expression Filling date: 20 Aug 2021 Issue date: 9 Aug 2022	20 Aug 2021	9 Aug 2022
Grant	Grant Utility: Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA Filling date: 12 Aug 2021 Issue date: 9 Aug 2022	12 Aug 2021	9 Aug 2022
Application	Application METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ALPHA-1 ANTITRYPSIN BY DOUBLE-STRANDED RNA Filling date: 30 Mar 2022 Issue date: 21 Jul 2022	30 Mar 2022	21 Jul 2022
Grant	Grant Utility: Compositions comprising reversibly modified oligonucleotides and uses thereof Filling date: 23 Aug 2017 Issue date: 19 Jul 2022	23 Aug 2017	19 Jul 2022
Grant	Grant Utility: Extended dicer substrate agents and methods for the specific inhibition of gene expression Filling date: 4 Jun 2021 Issue date: 14 Jun 2022	4 Jun 2021	14 Jun 2022
Grant	Grant Utility: Therapeutic inhibition of lactate dehydrogenase and agents therefor Filling date: 1 Jul 2020 Issue date: 14 Jun 2022	1 Jul 2020	14 Jun 2022
Application	Application DOUBLE-STRANDED NUCLEIC ACID INHIBITOR MOLECULES WITH SHORTENED SENSE STRANDS Filling date: 29 Apr 2020 Issue date: 9 Jun 2022	29 Apr 2020	9 Jun 2022
Grant	Grant Utility: Process for formulating an anionic agent Filling date: 19 Oct 2018 Issue date: 7 Jun 2022	19 Oct 2018	7 Jun 2022

DRNA patents

Dicerna Pharmaceuticals
Earnings Call Transcripts

Quarter	Transcript
Q3 2021 9 Nov 2021	Q3 2021 Earnings Call Transcript
Q2 2021 9 Aug 2021	Q2 2021 Earnings Call Transcript
Q1 2021 8 May 2021	Q1 2021 Earnings Call Transcript
Q4 2020 25 Feb 2021	Q4 2020 Earnings Call Transcript

DRNA earnings call transcripts

Dicerna Pharmaceuticals
Executives

Insider	Age	Compensation
Dr. Douglas M. Fambrough III (1969) Co-Founder, Chief Executive Officer, Pres & Director	56	$939,470
Dr. Bob D. Brown (1965) Executive Vice President of R&D and Chief Scientific Officer	60	$695,890
Mr. James B. Weissman (1962) Executive Vice President & Chief Operating Officer	63	$648,770
Mr. Douglas W. Pagan (1972) Chief Financial Officer	53	$515,650
Dr. Shreeram Aradhye M.D. (1963) Executive Vice President & Chief Medical Officer	62	$434,400

Dicerna Pharmaceuticals
Latest News

Tuesday, 28 December 2021
09:04	Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition	businesswire.com
09:04	Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition	businesswire.com
Saturday, 25 December 2021
08:00	Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna	businesswire.com
08:00	Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna	businesswire.com
Monday, 22 November 2021
17:48	Shares of RNAi Drug Companies Pop After Novo Lays Out $3.3 Billion for Dicerna	GuruFocus
Friday, 19 November 2021
11:30	Novo Nordisk (NVO) Set to Acquire Dicerna for $3.3 Billion	Zacks Investment Research
Thursday, 18 November 2021
13:56	Dicerna Pharmaceuticals acquired by Novo Nordisk; Shares rocket 80%	Invezz
11:38	Why Dicerna Pharmaceuticals Stock Is Rocketing Higher Today	The Motley Fool
11:01	LCID, RIVN, FSR: Why Are EV Stocks Down Today?	InvestorPlace
10:29	DRNA Stock: The $3B Novo Nordisk Deal That Has Dicerna Pharma Shares Skyrocketing Today	InvestorPlace
09:28	Novo Nordisk Swallows Dicerna In $3.3B Buyout: All You Need To Know	Benzinga
08:54	Why Novo Nordisk (NVO) Is Buying Dicerna Pharmaceuticals (DRNA) For $3.3 Billion	Pulse2
07:17	Novo Nordisk strikes $3.3 billion to buy research partner Dicerna Pharmaceuticals	Market Watch
Tuesday, 9 November 2021
14:54	Dicerna Pharmaceuticals, Inc. (DRNA) CEO Doug Fambrough on Q3 2021 Results - Earnings Call Transcript	Seeking Alpha
10:43	Dicerna Pharmaceuticals (DRNA) Reports Q3 Loss, Tops Revenue Estimates	Zacks Investment Research
08:13	Dicerna Pharmaceuticals: Q3 Earnings Insights	Benzinga
Tuesday, 19 October 2021
10:39	Dicerna Posts Mixed Nedosiran Data In Rare Kidney Disease Trial	Benzinga
07:30	Dicerna Announces Results for PHYOX™4, Single-Dose Study of Nedosiran in Primary Hyperoxaluria Type 3 (PH3)	Business Wire
Friday, 15 October 2021
16:01	Dicerna Announces Data to Be Presented at American Society of Nephrology (ASN) Kidney Week 2021	Business Wire
Thursday, 14 October 2021
16:54	Dicerna Announces Poster Presentations at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021 in November	Business Wire
Friday, 1 October 2021
16:38	Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Business Wire
Tuesday, 28 September 2021
07:30	Dicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorder	Business Wire
Wednesday, 22 September 2021
07:30	Dicerna Announces New Executive Leadership Appointments	Business Wire
Sunday, 22 August 2021
10:05	Dicerna's PH2 Failure Changes Everything	Seeking Alpha

Ideas & Opinions

Seeking Alpha 20 Nov 2021

Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment
Seeking Alpha 19 Nov 2021

Novo Nordisk Enhances Metabolic Disorder Pipeline With RNAi Drug Maker Dicerna
Seeking Alpha 22 Aug 2021

Dicerna's PH2 Failure Changes Everything
Seeking Alpha 6 Jul 2021

Arrowhead Pharmaceuticals Dives On Safety Issues For ARO-ENaC, But Remains On Track In Other Indications
Seeking Alpha 29 Jun 2021

Arbutus' Recent Hepatitis B Data At EASL 2021 Makes The Case For A Great Long-Term Investment
Seeking Alpha 11 May 2021

Dicerna A Buy On Long-Term Potential

Frequently Asked Questions (FAQ)

What's the price of Dicerna Pharmaceuticals stock today?

One share of Dicerna Pharmaceuticals stock can currently be purchased for approximately $38.22.
When is Dicerna Pharmaceuticals's next earnings date?

Unfortunately, Dicerna Pharmaceuticals's (DRNA) next earnings date is currently unknown.
Does Dicerna Pharmaceuticals pay dividends?

No, Dicerna Pharmaceuticals does not pay dividends.
What is Dicerna Pharmaceuticals's stock symbol?

Dicerna Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "DRNA".
What is Dicerna Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Dicerna Pharmaceuticals?

Shares of Dicerna Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Dicerna Pharmaceuticals's key executives?
Dicerna Pharmaceuticals's management team includes the following people:
- Dr. Douglas M. Fambrough III Co-Founder, Chief Executive Officer, Pres & Director(age: 56, pay: $939,470)
- Dr. Bob D. Brown Executive Vice President of R&D and Chief Scientific Officer(age: 60, pay: $695,890)
- Mr. James B. Weissman Executive Vice President & Chief Operating Officer(age: 63, pay: $648,770)
- Mr. Douglas W. Pagan Chief Financial Officer(age: 53, pay: $515,650)
- Dr. Shreeram Aradhye M.D. Executive Vice President & Chief Medical Officer(age: 62, pay: $434,400)
Is Dicerna Pharmaceuticals founder-led company?

Yes, Dicerna Pharmaceuticals is a company led by its founder Dr. Douglas M. Fambrough III.
How many employees does Dicerna Pharmaceuticals have?

As Jul 2024, Dicerna Pharmaceuticals employs 302 workers.
When Dicerna Pharmaceuticals went public?

Dicerna Pharmaceuticals, Inc. is publicly traded company for more then 11 years since IPO on 30 Jan 2014.
What is Dicerna Pharmaceuticals's official website?

The official website for Dicerna Pharmaceuticals is dicerna.com.
Where are Dicerna Pharmaceuticals's headquarters?

Dicerna Pharmaceuticals is headquartered at 33 HAYDEN AVENUE, Lexington, MASSACHUSETTS.
How can i contact Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals's mailing address is 33 HAYDEN AVENUE, Lexington, MASSACHUSETTS and company can be reached via phone at +1 617 621 8097.

Dicerna Pharmaceuticals, Inc.

dicerna.com

Exchange:

NASDAQ

Full time employees:

302

Industry:

Biotechnology

Sector:

Healthcare

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.

+1 617 621 8097

33 HAYDEN AVENUE
Lexington, MASSACHUSETTS 02421

CIK: 0001399529
ISIN: US2530311081
CUSIP: 253031108